NasdaqGS - Delayed Quote USD

Alnylam Pharmaceuticals, Inc. (ALNY)

143.31 -0.40 (-0.28%)
At close: April 26 at 4:00 PM EDT
146.71 +3.40 (+2.37%)
After hours: April 26 at 7:42 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,828,292.00
1,828,292.00
1,037,418.00
844,287.00
492,853.00
Cost of Revenue
310,406.00
310,406.00
168,817.00
140,144.00
78,052.00
Gross Profit
1,517,886.00
1,517,886.00
868,601.00
704,143.00
414,801.00
Operating Expense
1,800,061.00
1,800,061.00
1,653,673.00
1,412,795.00
1,243,239.00
Operating Income
-282,175.00
-282,175.00
-785,072.00
-708,652.00
-828,438.00
Net Non Operating Interest Income Expense
-25,660.00
-25,660.00
-131,160.00
-141,442.00
-72,687.00
Other Income Expense
-125,682.00
-125,682.00
-210,761.00
-2,050.00
45,525.00
Pretax Income
-433,517.00
-433,517.00
-1,126,993.00
-852,144.00
-855,600.00
Tax Provision
6,725.00
6,725.00
4,163.00
680.00
2,681.00
Net Income Common Stockholders
-440,242.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Diluted NI Available to Com Stockholders
-440,242.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Basic EPS
-4.11
-3.52
-9.30
-7.20
-7.46
Diluted EPS
-4.11
-3.52
-9.30
-7.20
-7.46
Basic Average Shares
124,320.75
124,906.00
121,689.00
118,451.00
114,986.00
Diluted Average Shares
124,320.75
124,906.00
121,689.00
118,451.00
114,986.00
Total Operating Income as Reported
-282,175.00
-282,175.00
-785,072.00
-708,652.00
-828,438.00
Rent Expense Supplemental
145,687.00
145,687.00
131,967.00
97,259.00
--
Total Expenses
2,110,467.00
2,110,467.00
1,822,490.00
1,552,939.00
1,321,291.00
Net Income from Continuing & Discontinued Operation
-440,242.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Normalized Income
-354,968.61
-354,968.61
-969,555.97
-865,425.26
-885,186.61
Interest Income
95,561.00
95,561.00
24,808.00
1,579.00
11,809.00
Interest Expense
121,221.00
121,221.00
155,968.00
143,021.00
84,496.00
Net Interest Income
-25,660.00
-25,660.00
-131,160.00
-141,442.00
-72,687.00
EBIT
-312,296.00
-312,296.00
-971,025.00
-709,123.00
-771,104.00
EBITDA
-215,265.00
-215,265.00
-885,475.00
-619,429.00
-696,669.00
Reconciled Cost of Revenue
310,406.00
310,406.00
168,817.00
140,144.00
78,052.00
Reconciled Depreciation
97,031.00
97,031.00
85,550.00
89,694.00
74,435.00
Net Income from Continuing Operation Net Minority Interest
-440,242.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Total Unusual Items Excluding Goodwill
-107,941.00
-107,941.00
-204,557.00
17,262.00
36,857.00
Total Unusual Items
-107,941.00
-107,941.00
-204,557.00
17,262.00
36,857.00
Normalized EBITDA
-107,324.00
-107,324.00
-680,918.00
-636,691.00
-733,526.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-22,667.61
-22,667.61
-42,956.97
4,660.74
9,951.39
12/31/2020 - 6/1/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARWR Arrowhead Pharmaceuticals, Inc.
22.12
+1.14%
 
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
 
IONS Ionis Pharmaceuticals, Inc.
41.59
-0.60%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
INCY Incyte Corporation
51.68
+0.98%
 
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
 
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%
 
LEGN Legend Biotech Corporation
45.30
+1.98%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%